Ultima Genomics presented early TRACERx minimal residual disease (MRD) results at AACR emphasizing ppmSeq’s ultra-sensitive circulating tumor DNA (ctDNA) detection. The company described data from a validation pilot across 50 plasma samples using tumor-specific variants derived from prior whole-genome sequencing. In the long-running TRACERx program—funded by Cancer Research UK and analyzing multi-region, multi-time-point lung cancer data—ppmSeq’s analytical sensitivity is reported as reaching low single-digit parts-per-million ctDNA detection in the plasma samples. AACR session materials also highlight specificity data from an independent analytical study coordinated with Labcorp across multiple solid tumor types. The presentations position ppmSeq as a candidate technology for expanding MRD monitoring to broader patient cohorts and, ultimately, deployment at healthcare-system scale.